Trial Profile
Open-label, Multi Center PET/CT (Positron Emission Tomography/Computed Tomography) Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 68Ga Labeled PET Tracer BAY86-7548 Following a Single Intravenous Administration of 140 MBq (Corresponding to ≤28 µg Mass Dose) in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Apr 2019
Price :
$35
*
At a glance
- Drugs Gallium 68 RM2 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Sponsors Life Molecular Imaging; Piramal Imaging
- 27 Mar 2019 According to a Life Molecular Imaging, Piramal imaging changed its name to Life Molecular Imaging.
- 13 Nov 2014 New trial record